Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

JAMA - 8 Sept 2026

Zhou Ting, Zhou Huaqiang, Gao Fangfang, Feng Weineng, Jiang Wei, Huang Lu, Zhao Feifei, Chen Lili, Ji Mei, Zhu Junfei, Fang Yong, Chen Peirui, Wang Peng, Wu Jingxun, Zhuang Li, Liu Xiting, Deng Meiyu, Weng Guixiang, Li Jibin, Yang Chunyan, Zhao Hongyun, Yang Yunpeng, Zhang Li

Abstract excerpt

Importance: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients most likely to derive benefit from such regimens remains an unmet clinical need. Objective: To prospectively compare the efficacy and...

Read the complete abstract on PubMed

Topics

Adult
Aged
Female
Humans
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Acrylamides

Aniline Compounds

Antineoplastic Combined Chemotherapy Protocols

Carboplatin

Carcinoma, Non-Small-Cell Lung

ErbB Receptors

Indoles

Lung Neoplasms

Mutation

Pemetrexed

Prospective Studies

Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 42574006
DOI: 10.1001/jama.2026.10599
PMCID: PMC13458949

Genes

EGFR
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.PMID 42574006Read ↗

Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort StudySemantic proximity Read ↗

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.Semantic proximity Read ↗

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).Semantic proximity Read ↗

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.Semantic proximity Read ↗

Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

First-line Osimertinib for Poor Performance Status Patients With EGFR Mutation-positive Non-small Cell Lung Cancer: A Prospective Observational StudySemantic proximity Read ↗

New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era.Semantic proximity Read ↗

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.Semantic proximity Read ↗

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.Semantic proximity Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.